SCHEMBL4773108

SCHEMBL4773108

CC(C)(C)NC(=O)OC1CCC(=O)NC1=O

nearest known ligand 0.46

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 20/20 0.46
CRBN Q96SW2 20/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28864213 0.84 GAA (0.34) DDB1CRBN
SCHEMBL28614908 0.84 GAA (0.34) DDB1CRBN
SCHEMBL28500818 0.78 CCR2 (0.38)
SCHEMBL26328452 0.77 DDB1 (0.52) DDB1CRBN
SCHEMBL28213541 0.76 CCR2 (0.42)
SCHEMBL7088944 0.75 CCR2 (0.48)
SCHEMBL27638680 0.75 CCR2 (0.48)
SCHEMBL29129941 0.74 CCNT1 (0.31)
SCHEMBL28666934 0.74 DDB1 (0.47) DDB1CRBN
SCHEMBL28958060 0.74 DDB1 (0.47) DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112105385-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2020-12-18 CN disclosed
CN-103626738-B A kind of pool horse degree amine crystal formation and preparation method thereof Chongqing Taihao Pharmaceutical Co., Ltd. (CN) 2016-03-16 CN disclosed
CN-103497174-B Moor preparation and the process for purification of sharp degree amine Hangzhou Pai Chen Pharmaceutical Technology Co., Ltd (CN) 2015-10-28 CN disclosed
CN-103626738-A Pomalidomide crystal and preparation method thereof CHONGQING TAIHAO PHARMACEUTICAL CO LTD 2014-03-12 CN disclosed
CN-103497174-A Preparation and refining method of pomalidomide HANGZHOU PIOPHARM PHARMACEUTICAL TECHNOLOGY CO LTD 2014-01-08 CN disclosed
US-8524742-B2 Use of 5H-thioeno(3,4-c)pyrrole-4,6-dione derivatives as tumor necrosis factor inhibitor TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2013-09-03 US disclosed
EP-1964842-B1 5H-THIENO [3,4-c]PYRROLE-4, 6-DIONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR TIAN JIN HEMAY BIO TECH CO LTD (CN) 2012-09-12 EP disclosed
US-20120220631-A1 USE OF 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AS TUMOR NECROSIS FACTOR INHIBITOR TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2012-08-30 US disclosed
US-8183260-B2 small molecule, low toxicity, high efficiency, high economic value; 5-(2,6-dioxopiperidin-3-yl)-5H-thieno(3,4-c)pyrrole-4,6-dione: TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2012-05-22 US disclosed
EP-1964842-A1 5H-THIENO [3,4-c]PYRROLE-4, 6-DIONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR Tian Jin Hemay Bio-Tech Co., Ltd. (CN) 2008-09-03 EP disclosed
US-20080176900-A1 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220631-A1 USE OF 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AS TUMOR NECROSIS FACTOR INHIBITOR TNF, TPMT, TNFRSF1A DDB1 790/4885CRBN 1305/4885
US-20080176900-A1 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TNF, TNFRSF1A, CD40 DDB1 1951/4885CRBN 938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.